18F-FDG Uptake by Metastatic Axillary Lymph Nodes on Pretreatment PET/CT as a Prognostic Factor for Recurrence in Patients with Invasive Ductal Breast Cancer
Authors:
- Sang-Woo LeeSLSang-Woo Lee
- Shin Young JeongSJShin Young Jeong
- Yee Soo ChaeYCYee Soo Chae
- Won Kee LeeWLWon Kee Lee
- Byeong-Cheol AhnBAByeong-Cheol Ahn
- Jaetae LeeJLJaetae Lee
- 29 June 2012
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 53 (9) , 1337-1344
Abstract
This study assessed the maximum standardized uptake value of metastatic axillary lymph nodes in patients with invasive ductal breast cancer (IDC) to determine the pretreatment prognostic value of (18)F-FDG PET/CT for disease-free survival (DFS). Sixty-five female IDC patients who had undergone pretreatment (18)F-FDG PET/CT and had pathologically confirmed axillary lymph node involvement without distant metastasis were enrolled. All patients showed complete remission after first-line treatment. To obtain nodal SUVmax, a transaxial image representing the highest (18)F-FDG uptake was carefully selected and a region of interest was manually drawn on the (18)F-FDG-accumulating lesion. Clinicopathologic parameters such as age, TNM stage, estrogen receptor status, progesterone receptor status, human epidermal growth factor receptor 2 status, and primary-tumor and nodal SUVmax on PET were analyzed for their usefulness in predicting recurrence. Combinatorial effects and interactions between variables that were significant by univariate analysis were examined using multivariate Cox proportional-hazards models. Twelve of 65 patients (18.5%) experienced recurrence during follow-up (median follow-up, 36 mo; range, 21-57 mo). Nodal SUVmax was significantly higher in patients with recurrence than in those who were disease-free (recurrence group: 5.2 ± 2.3, vs. disease-free group: 1.9 ± 1.9, P < 0.0001). A receiver-operating-characteristic curve demonstrated a nodal SUVmax of 2.8 (sensitivity, 91.7%; specificity, 86.8%; area under the curve, 0.890) to be the optimal cutoff for predicting DFS. Univariate analysis revealed that T stage, N stage, estrogen receptor status, and primary-tumor and nodal SUVmax correlated significantly with DFS. Among these 5 variables, only nodal SUVmax was found to be a single determinant of DFS by multivariate analysis (hazard ratio, 31.54; 95% confidence interval, 2.66-373.39; P = 0.0065). Nodal SUVmax on pretreatment (18)F-FDG PET/CT may be an independent prognostic factor for disease recurrence in patients with IDC.Keywords
This publication has 30 references indexed in Scilit:
- Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast CancerNuclear Medicine and Molecular Imaging, 2011
- Can 18F-FDG PET/CT predict recurrence in patients with cutaneous malignant melanoma?Nuklearmedizin-Nuclear Medicine, 2011
- Preoperative [18F]-fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes may aid in selecting patients with oral cavity squamous cell carcinoma for salvage therapy after relapseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Predictive and prognostic value of FDG-PETCancer Imaging, 2008
- Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's diseaseAnnals of Oncology, 2004
- Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18f]fluoro-2-deoxy-d-glucoseInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Positron Emission Tomography Scanning: Current and Future ApplicationsAnnual Review of Medicine, 2002
- Prognostic Importance of the Standardized Uptake Value on 18F-Fluoro-2-Deoxy-Glucose–Positron Emission Tomography Scan in Non–Small-Cell Lung Cancer: An Analysis of 125 CasesJournal of Clinical Oncology, 1999
- Relation of tumor size, lymph node status, and survival in 24,740 breast cancer casesCancer, 1989
- Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP updateCancer, 1983